BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Research

Samsung Biologics Partners With Coalition for Epidemic Preparedness Innovations To Boost Outbreak Ready Vaccine Manufacturing

The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organiz...

February 05, 2026 | News

SK bioscience Advances Early Clinical RSV Preventive Monoclonal Antibody Licensed From Gates Medical Research Institute

SK to advance novel early-clinical stage RSV preventive monoclonal antibody in-licensed from Gates Medical Research Institute Exclusive rights to commer...

February 05, 2026 | News

GHIT Fund Commits JPY 1.39 Billion To Back Six R&D Programmes Across Malaria, Tuberculosis And Neglected Tropical Diseases

The Global Health Innovative Technology (GHIT) Fund announced a total investment of approximately JPY 1.39 billion (USD 8.8 million1) in six R&D projec...

February 04, 2026 | News

WuXi Biologics Partners With Vertex To Advance Trispecific T Cell Engager For Autoimmune Diseases

WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it has signed a license ...

February 04, 2026 | News

Bioxytran Strengthens Carbohydrate Science Platform Through Sponsored Research With University of Minnesota

Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform ...

February 04, 2026 | News

Monash Innovation Labs And Agilent Technologies Australia Deepen Applied Research Partnership

Monash Innovation Labs and Agilent Technologies Australia have formalised a new partnership to embed advanced analytical instrumentation wit...

February 03, 2026 | News

Ascletis Pharma Reports Positive Phase III Safety Results For Denifanstat In Moderate To Severe Acne

Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label ...

February 03, 2026 | News

AstraZeneca Commits $15 Billion Investment To Expand R&D And Manufacturing Footprint In China Through 2030

Landmark investment will expand AstraZeneca’s capabilities to discover, develop, and manufacture transformative new treatments in China In...

February 03, 2026 | News

Merck Strengthens India As A Strategic Healthcare R&D Growth Engine With New Innovation Hub

A workplace designed for long-term growth, efficiency, and innovation Elevating Merck Healthcare’s R&D India Hub as a premier talent powerho...

February 02, 2026 | News

Turning Frontline Reality Into Policy Action For Cancer Care In Asia

Drawing on her frontline clinical experience in Malaysia, Prof Dr Wan Zamaniah, Consultant Clinical Oncologist, University Malaya Medical Centre&...

February 02, 2026 | Expert Insight

Kazia Therapeutics Advances First In Class Nuclear PD L1 Protein Degrader With Compelling Preclinical Evidence

Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, announced co...

February 02, 2026 | News

Fidēs Launches Science Led Imaging CRO Focused On Early Phase Clinical Decision Making

Fidēs announced its launch as a new imaging contract research organization (iCRO) designed specifically for early-phase clinical development, where imagin...

February 02, 2026 | News

Telix Pharmaceuticals Limited Doses First Patient In Japan Phase 3 Study Of Illuccix For Prostate Cancer Imaging

Telix Pharmaceuticals Limited announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for ...

January 30, 2026 | News

Drug Farm Secures FDA Fast Track Designation For First In Class ALPK1 Inhibitor DF 003 In ROSAH Syndrome

Drug Farm, a clinical-stage biopharmaceutical company advancing two novel small molecule drugs for ROSAH syndrome and hepatitis B, announced that the U.S. ...

January 30, 2026 | News

Stay Connected